ES2154277T3 - Combinacion farmaceutica que contiene un inhibidor del sistema renina-angiotensina y un antagonista de endotelina. - Google Patents

Combinacion farmaceutica que contiene un inhibidor del sistema renina-angiotensina y un antagonista de endotelina.

Info

Publication number
ES2154277T3
ES2154277T3 ES94110064T ES94110064T ES2154277T3 ES 2154277 T3 ES2154277 T3 ES 2154277T3 ES 94110064 T ES94110064 T ES 94110064T ES 94110064 T ES94110064 T ES 94110064T ES 2154277 T3 ES2154277 T3 ES 2154277T3
Authority
ES
Spain
Prior art keywords
inhibitor
pharmaceutical combination
renine
angiotensin system
combination containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94110064T
Other languages
English (en)
Inventor
Jean-Paul Clozel
Martine Clozel
Wolfgang Osterrieder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2154277T3 publication Critical patent/ES2154277T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

SE DESCRIBEN PREPARADOS DE COMBINACIONES FARMACEUTICAS, QUE CONTIENEN UN INHIBIDOR DEL SISTEMA RENINA-ANGIOTENSINA ("INHIBIDOR RAS") Y UN ANTAGONISTA ENDOTELINA. ESTE PREPARADO ES ADECUADO PARA LA LUCHA O IMPEDIMENTO DE LA HIPERTENSION Y LAS ENFERMEDADES CONSECUENTES ASI COMO PARA EL TRATAMIENTO DE LA INSUFICIENCIA CARDIACA.
ES94110064T 1993-07-15 1994-06-29 Combinacion farmaceutica que contiene un inhibidor del sistema renina-angiotensina y un antagonista de endotelina. Expired - Lifetime ES2154277T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH213193 1993-07-15

Publications (1)

Publication Number Publication Date
ES2154277T3 true ES2154277T3 (es) 2001-04-01

Family

ID=4226611

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94110064T Expired - Lifetime ES2154277T3 (es) 1993-07-15 1994-06-29 Combinacion farmaceutica que contiene un inhibidor del sistema renina-angiotensina y un antagonista de endotelina.

Country Status (25)

Country Link
US (1) US5696116A (es)
EP (1) EP0634175B1 (es)
JP (1) JP2746537B2 (es)
KR (1) KR100370181B1 (es)
CN (1) CN1105573C (es)
AT (1) ATE198551T1 (es)
AU (1) AU683262B2 (es)
BR (1) BR9402815A (es)
CA (1) CA2128142C (es)
CZ (1) CZ285413B6 (es)
DE (1) DE59409631D1 (es)
DK (1) DK0634175T3 (es)
ES (1) ES2154277T3 (es)
GR (1) GR3035702T3 (es)
HU (1) HU221202B1 (es)
IL (1) IL110272A (es)
NO (1) NO312578B1 (es)
NZ (1) NZ260969A (es)
PL (1) PL176445B1 (es)
PT (1) PT634175E (es)
RU (1) RU2146522C1 (es)
SA (1) SA94150155B1 (es)
TW (1) TW287949B (es)
UA (1) UA27870C2 (es)
ZA (1) ZA944980B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
KR19990087063A (ko) 1996-02-20 1999-12-15 스티븐 비. 데이비스 비페닐 이속사졸 술폰아미드의 제조 방법
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
WO1998033781A1 (en) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
JP4917707B2 (ja) * 1997-09-26 2012-04-18 アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト エンドセリン拮抗剤およびレニン−アンギオテンシン系阻害剤から成る組合せ剤
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
ES2552639T3 (es) * 1998-07-10 2015-12-01 Novartis Pharma Ag Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos
US6136971A (en) * 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
CN101011390A (zh) * 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
AU3718900A (en) 1999-03-19 2000-10-09 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
DK1486206T3 (da) * 2000-08-25 2008-02-11 Res Corp Technologies Inc Anvendelse af antikonvulsiv aminosyre til behandling af bipolære sygdomme
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
RU2201255C1 (ru) * 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
EP1517682B1 (en) * 2002-06-28 2006-11-02 Speedel Pharma AG Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant
WO2005018642A1 (en) * 2003-08-22 2005-03-03 Schering Aktiengesellschaft Chemokine inhibiting piperazine derivatives and their use to treat myocarditis
WO2007066678A1 (ja) * 2005-12-06 2007-06-14 Santen Pharmaceutical Co., Ltd. 角結膜障害治療剤
EP2091539A1 (en) * 2006-12-12 2009-08-26 Gilead Colorado, Inc. Ambrisentan combined with a renin inhibitor for hypertensive disorder
US8080549B2 (en) * 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
WO2008088727A2 (en) 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
IL315563A (en) 2017-02-27 2024-11-01 Idorsia Pharmaceuticals Ltd Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642785A (en) * 1969-08-11 1972-02-15 Merck & Co Inc Indenyl-3-aliphatic amines
DE2117571C3 (de) * 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
JPS559058A (en) * 1978-07-06 1980-01-22 Dainippon Pharmaceut Co Ltd 1-(3-mercapto-2-methylpropanoyl)prolyl amino acid derivative
US4316906A (en) * 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4470972A (en) * 1981-04-28 1984-09-11 Schering Corporation 7-Carboxyalkylaminoacyl-1,4-dithia-7-azaspiro[4.4]-nonane-8-carboxylic acids
US4337201A (en) * 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
AT377496B (de) * 1981-06-19 1985-03-25 Voith Gmbh J M Vorrichtung zum anwickeln einer warenbahn auf eine neu eingelegte wickelhuelse in einer doppeltragwalzen-wickelmaschine
US4410520A (en) * 1981-11-09 1983-10-18 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
GB2128984B (en) * 1982-05-12 1985-05-22 Hoffmann La Roche Diaza-bicyclic compounds
DE3542794A1 (de) * 1985-12-04 1987-06-11 Bayer Ag Antihypertensives kombinationspraeparat
EP0334164B1 (de) * 1988-03-24 1993-10-27 F. Hoffmann-La Roche Ag Antihypertensives Kombinationspräparat
WO1992013545A1 (en) * 1991-01-31 1992-08-20 Abbott Laboratories Endothelin converting enzyme inhibitors
DE69221175T2 (de) * 1991-02-07 1998-01-15 Roussel Uclaf Bizyklische Stickstoffverbindungen, ihre Herstellung, erhaltene Zwischenprodukte, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammensetzungen
MX9200299A (es) * 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW216770B (es) * 1991-07-23 1993-12-01 Hoffmann La Roche
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5420123A (en) * 1992-12-21 1995-05-30 Bristol-Myers Squibb Company Dibenzodiazepine endothelin antagonists

Also Published As

Publication number Publication date
IL110272A (en) 1998-07-15
UA27870C2 (uk) 2000-10-16
HUT67331A (en) 1995-03-28
HU9402064D0 (en) 1994-09-28
CZ285413B6 (cs) 1999-08-11
US5696116A (en) 1997-12-09
IL110272A0 (en) 1994-10-21
PL176445B1 (pl) 1999-05-31
ATE198551T1 (de) 2001-01-15
KR960013371A (ko) 1996-05-22
GR3035702T3 (en) 2001-07-31
NO312578B1 (no) 2002-06-03
NO942650D0 (no) 1994-07-14
HU221202B1 (en) 2002-08-28
AU683262B2 (en) 1997-11-06
EP0634175A1 (de) 1995-01-18
BR9402815A (pt) 1995-04-04
CN1105573C (zh) 2003-04-16
NZ260969A (en) 1996-01-26
ZA944980B (en) 1995-02-06
CN1107364A (zh) 1995-08-30
CA2128142A1 (en) 1995-01-16
RU2146522C1 (ru) 2000-03-20
RU94026283A (ru) 1996-05-20
NO942650L (no) 1995-01-16
DE59409631D1 (de) 2001-02-15
DK0634175T3 (da) 2001-04-30
CA2128142C (en) 2007-03-06
SA94150155B1 (ar) 2005-11-15
CZ167794A3 (en) 1995-01-18
PT634175E (pt) 2001-06-29
EP0634175B1 (de) 2001-01-10
KR100370181B1 (ko) 2003-04-26
JPH0753408A (ja) 1995-02-28
JP2746537B2 (ja) 1998-05-06
PL304292A1 (en) 1995-01-23
TW287949B (es) 1996-10-11
AU6735794A (en) 1995-01-27

Similar Documents

Publication Publication Date Title
ES2154277T3 (es) Combinacion farmaceutica que contiene un inhibidor del sistema renina-angiotensina y un antagonista de endotelina.
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
NO962162D0 (no) Dipeptider som bevirker frigjöring av veksthormon
GT199800126A (es) Terapia de combinacion.
DK0705100T3 (da) Terapeutiske substituerede guanidiner
FI935172A7 (fi) Katepsiini G:n ja elastaasin inhibiittoreita sidekudoksen rappeutumise n ehkäisemistä varten
FI901148A0 (fi) Tetrahydrokinolinderivat som aer anvaendbara vid vaord av neurodegenerativa stoerningar.
TR199900505T2 (es)
NO975234D0 (no) Fremgangsmåte for behandling av maniske og bipolare forstyrrelser
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
ES2186807T3 (es) Inhibidores de trombina.
DE59810600D1 (de) Endothelin antagonist und renin-angiotensin system hemmer als kombinationspräparate
TR199801988T2 (xx) Kalp yetmezli�inin endotelin antagonistleri ile tedavisi i�in y�ntem.
FI962369L (fi) Farmaseuttinen formulointi myrkytyksen ehkäisemiseksi tai esihoidoksi organofosforisilla koliiniesteraasi-inhibiittoreilla
NO934832D0 (no) Farmasoeytisk sammensetning for forhindring eller behandling av ar terioscherose
ES2150418T3 (es) Composiciones farmaceuticas que comprenden calcitonina.
EP0653208A3 (en) Substance P antagonists for the treatment or prevention of sunburn.
MX9302142A (es) Uso de 3r- y 3r,s-difenilmetoxi-1-(3,4-metileno-dioxifenetil)-piperidina y composicion que la contienen.
BG97168A (bg) Брадикинин-антагонисти за лечение на остър панкреатит
ES2106098T3 (es) Lacidipino para el tratamiento de la arteriosclerosis.
ITRM920743A0 (it) Irrigatore automatico e/o manuale per la termostabilizzazione del corpo.
ITFI930163A1 (it) Procedimento, centralina e prodotto per la disinfezione di acque di piscina.
ITTO921027A0 (it) Priocedimento e impianto per disinfettare o sterilizzare i rifiuti.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 634175

Country of ref document: ES